A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female Volunteers

NCT ID: NCT02171780

Last Updated: 2014-06-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 122 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-02-28

Brief Summary

To investigate safety, tolerability, and pharmacokinetics of BI 1744 CL

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

BI 1744 CL single rising doses

Group Type: EXPERIMENTAL

BI 1744 CL

Intervention Type: DRUG

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

BI 1744 CL

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• The subject is healthy based upon a complete medical history, including the physical examination, regarding vital signs (BP, PR), 12-lead ECG measurement, and clinical laboratory tests. There is no finding deviating from normal and of clinical relevance. There is no evidence of a clinically relevant concomitant disease
• The subject is at least 21 years old and not older than 50 years
• The subject's body mass index (BMI) is at least 18.5 kg/m2 and less than 30 kg/m2
• The subject has signed and dated a written informed consent prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation

Exclusion Criteria

• The subject has any finding of the medical examination (including BP, PR, and ECG measurements) deviating from normal and of clinical relevance
• The subject had a surgery of gastrointestinal tract (except appendectomy)
• The subject has a diagnosis of gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
• The subject has a diagnosis of diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
• The subject has a history of relevant orthostatic hypotension, fainting spells or blackouts
• The subject has a diagnosis of chronic or relevant acute infections
• The subject has a history of relevant allergy/hypersensitivity (including allergy to the drug or its excipients) as judged clinically relevant by the investigator
• The subject has taken drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to randomisation
• The subject has used drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to randomisation
• The subject has participated in another trial with an investigational drug within two months prior to randomisation
• The subject is a heavily smoker (>10 cigarettes or >3 cigars or >3 pipes/day)
• The subject is not able to refrain from smoking on trial days as judged by the investigator
• The subject uses more than 60 g alcohol a day)
• The subject uses drugs
• The subject has donated more than 100 mL blood within four weeks prior to randomisation
• The subject has performed excessive physical activities within one week prior to randomisation
• The subject has a laboratory value outside the reference range that is of clinical relevance
• The subject is not able to comply with dietary regimen of the study centre.

• The subject has a diagnosis of asthma or history of pulmonary hyperreactivity
• The subject has a diagnosis of hyperthyrosis
• The subject has a diagnosis of allergic rhinitis in need of treatment
• The subject has a diagnosis of clinically relevant cardiac arrhythmia
• The subject has a diagnosis of paroxysmal tachycardia (>100 beats per minute).

For female subjects:

• Pregnancy
• Positive pregnancy test
• No adequate contraception e.g. oral contraception, sterilisation, IUD (intrauterine device). Females who are not surgically sterile will be asked to additionally use barrier contraception methods (e.g. condoms) prior to administration of study medication, during the study and at least one month after release from the study
• Inability to maintain this adequate contraception during the whole study period
• Lactation period

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Boehringer Ingelheim

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

1222.1

Identifier Type: -

Identifier Source: org_study_id